Regenerative Stem Cell Therapy for Stroke in Europe 1-RESSTORE1

Summary

Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke recovery and patients quality of life.

Conditions

• Stroke

Interventions

DRUG

Adipose derived Stem Cell

4 doses

OTHER

placebo

placebo

Sponsors & Collaborators

• Horizon 2020 - European Commission

  collaborator OTHER

• University Grenoble Alps

  collaborator OTHER

• Servicio Madrileño de Salud, Madrid, Spain

  collaborator OTHER

• St. Anne's University Hospital Brno, Czech Republic

  collaborator OTHER

• Andaluz Health Service

  collaborator OTHER_GOV

• University of Glasgow

  collaborator OTHER

• University of Eastern Finland

  collaborator OTHER

• Etablissement Français du Sang

  collaborator OTHER

• Tampere University

  collaborator OTHER

• Histocell SL, Spain

  collaborator UNKNOWN

• Oy Medfiles Ltd

  collaborator INDUSTRY

• Institut National de la Santé Et de la Recherche Médicale, France

  collaborator OTHER_GOV

• Hospices Civils de Lyon

  collaborator OTHER

• Association Groupe ESSEC

  collaborator OTHER

• NOVADISCOVERY SAS, France

  collaborator UNKNOWN

• Finovatis

  collaborator OTHER

• Centre Hospitalier Universitaire de Besancon

  collaborator OTHER

• Assistance Publique - Hôpitaux de Paris

  collaborator OTHER

• University Hospital, Toulouse

  collaborator OTHER

• University Hospital, Bordeaux

  collaborator OTHER

• University Hospital, Caen

  collaborator OTHER

• Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León

  collaborator OTHER

• Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

  collaborator OTHER

• Servicio de Salud de Castilla La Mancha, Albacete, Spain

  collaborator UNKNOWN

• Servicio Gallego de Salud

  collaborator OTHER_GOV

• Pirkanmaa Hospital District, Tampere, Finland

  collaborator UNKNOWN

• Hospital Vall d'Hebron

  collaborator OTHER

• Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

  collaborator OTHER

• CH Sainte-Anne, Paris, France

  collaborator UNKNOWN

• University Hospital, Grenoble

  lead OTHER

Principal Investigators

• Olivier Detante, MD PhD · University Hospital Grenoble-Alpes

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-06-02

Primary Completion

2025-07-01

Completion

2027-07-01

Countries

• France

Study Locations